Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALTAN: Palbociclib + Letrozole + Trastuzumab in ER+ HER2+ Breast Cancer
NCT02907918Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Washington University School of Medicine. Primary endpoint: Pathologic Complete Response at 16 weeks. Started Jun 2017; status: terminated.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02907918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907918.